CTNM Stock Overview
A clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Contineum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.57 |
| 52 Week High | US$22.00 |
| 52 Week Low | US$3.35 |
| Beta | 0 |
| 1 Month Change | -19.05% |
| 3 Month Change | -49.29% |
| 1 Year Change | -76.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.82% |
Recent News & Updates
Shareholder Returns
| CTNM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.7% | -0.2% | 0.8% |
| 1Y | -76.2% | -10.5% | 11.5% |
Return vs Industry: CTNM underperformed the US Pharmaceuticals industry which returned -10.5% over the past year.
Return vs Market: CTNM underperformed the US Market which returned 11.5% over the past year.
Price Volatility
| CTNM volatility | |
|---|---|
| CTNM Average Weekly Movement | 13.8% |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: CTNM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CTNM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 41 | Carmine Stengone | www.contineum-tx.com |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate.
Contineum Therapeutics, Inc. Fundamentals Summary
| CTNM fundamental statistics | |
|---|---|
| Market cap | US$87.96m |
| Earnings (TTM) | -US$49.83m |
| Revenue (TTM) | n/a |
Is CTNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTNM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$49.83m |
| Earnings | -US$49.83m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CTNM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 23:13 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Contineum Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |
| Sean Laaman | Morgan Stanley |